Acasti Pharma Inc. | Income Statement
Fiscal year is April-March. All values CAD Thousands.
2014
2015
2016
2017
2018
2019
Sales/Revenue
500.90
270.60
37.70
-
-
-
Cost of Goods Sold (COGS) incl. D&A
2,065.70
2,570.30
2,475.90
2,527.40
2,672.00
2,827
Gross Income
1,564.80
2,299.70
2,438.20
2,527.40
2,672.00
2,827
SG&A Expense
9,504.50
10,359.00
7,002.90
7,820.20
17,433.00
41,786
EBIT
11,069.30
12,658.70
9,441.10
10,347.60
20,105.00
44,613
Unusual Expense
507.40
8,824.10
1,861.90
53.00
344.00
7,277
Non Operating Income/Expense
336.80
1,828.70
1,020.20
162.10
1,166.00
374
Interest Expense
-
-
-
53.50
370.00
365
Pretax Income
11,881.20
1,919.00
6,485.50
10,500.80
21,913.00
52,154
Income Tax
269.60
264.30
168.80
119.10
409.00
588
Consolidated Net Income
11,611.60
1,654.70
6,316.70
10,381.80
21,504.00
51,566
Net Income
11,611.60
1,654.70
6,316.70
10,381.80
21,504.00
51,566
Net Income After Extraordinaries
11,611.60
1,654.70
6,316.70
10,381.80
21,504.00
51,566
Net Income Available to Common
11,611.60
1,654.70
6,316.70
10,381.80
21,504.00
51,566
EPS (Basic)
1.38
0.16
0.59
0.86
1.23
0.95
Basic Shares Outstanding
8,436.90
10,617.70
10,659.90
11,094.50
17,486.50
54,290.30
EPS (Diluted)
1.38
0.16
0.59
1.01
1.23
0.95
Diluted Shares Outstanding
8,436.90
10,617.70
10,659.90
11,094.50
17,486.50
54,290.30
EBITDA
9,295.50
10,323.50
7,046.60
7,820.20
17,433.00
41,786
Non-Operating Interest Income
32.30
87.00
73.50
115.40
72.00
475
About Acasti Pharma
View Profile
